AKT1 and adrenal cortex carcinoma: In contrast, in tissue microarrays of 45 ACC patients who received mitotane monotherapy, in which p-Akt was detected in 31% of tumors, Hermsen et al. (86) unexpectedly found an association between p-Akt expression and longer overall survival, although there was no association with objective response to mitotane.